**A Systematic Review and Meta-analysis**

The aim of this study was to compare the efficacies of systemic treatments with dupilumab, tralokinumab and Janus kinase inhibitors for moderate-to-severe atopic dermatitis. A systematic review following Preferred Reporting Items for Systemic Reviews and Meta-Analyses (PRISMA) guidelines was performed using Medline, EMBASE and Cochrane library. All randomized controlled trials investigating the efficacy of systemic treatments for moderate-to-severe atopic dermatitis in adults were included. Primary outcomes were the proportion of patients with atopic dermatitis achieving 50%, 75%, and 90% improvement in Eczema Area and Severity Index (EASI) score after dupilumab, tralokinumab or Janus kinase inhibitors. Nineteen studies totalling 6,444 patients were included. In monotherapy studies, upadacitinib 30 mg once daily had the numerically highest efficacy regarding EASI-50, EASI-75 and EASI-90. In combination therapy studies with topical corticosteroids, dupilumab 300 mg every other week had highest efficacy regarding EASI-50, and abrocitinib 200 mg once daily had the highest score regarding EASI-75 and EASI-90. Analysis provided evidence that dupilumab, tralokinumab and Janus kinase inhibitors all had an acceptable efficacy profile and resulted in clinically relevant improvements in EASI score. Furthermore, upadacitinib and abrocitinib seem to have great potential to treat patients with atopic dermatitis. However, further studies are needed to determine the long-term efficacy of Janus kinase inhibitors in adults with moderate-to-severe atopic dermatitis.

**Key words:** atopic dermatitis; systemic; biological.

Accepted Jul 12, 2022; Epub ahead of print Jul 12, 2022

Acta Derm Venereol 2022; 102: adv00764.

DOI: 10.2340/actadv.v102.2075

Corr: Farnam Barati Sedeh, Department of Dermato-Venereology, Zealand University Hospital, Roskilde, Denmark. E-mail: farnam07@hotmail.com

**SIGNIFICANCE**

Atopic dermatitis can, in most cases, be adequately controlled with topical treatments alone or in combination with phototherapy. However, in moderate-to-severe atopic dermatitis, systemic therapy may be needed for adequate disease control. Dupilumab, tralokinumab and Janus kinase inhibitors are some of the newly developed systemic treatments. The aim of this review was to investigate the efficacy of these treatments, which is an urgent need to implement evidence-based practice guidelines, to ensure the best possible patient care. This study suggests that patients who have moderate-to-severe atopic dermatitis that is unresponsive to topical therapies may benefit from treatment with dupilumab, tralokinumab, or Janus kinase inhibitors.

Reduced quality of life have all been associated with worsening of AD (4–7).

Regarding treatment of AD, the strategy is based heavily on current disease severity. Severity of AD can be divided into 3 groups: mild, moderate, and severe. Mild and moderate AD can usually be managed with a combination of moisturizing creams, topical corticosteroids (TCS) or calcineurin inhibitors and phototherapy. Approximately 2% of patients have recalcitrant AD, which does not respond to this regimen, and require a variety of systemic immunosuppressive or antimicrobial treatments in combination or sequentially (8, 9). Generally, most common immunosuppressors (methotrexate, azathioprine and mycophenolate mofetil) are used as off-label drugs in treatment of moderate-to-severe AD, when conventional treatment with TCS or phototherapy fails. Systemic corticosteroids can be used as treatment for acute exacerbations, but they are not recommended for long-term treatment in AD due to side-effects (10–12). Cyclosporine is the only approved treatment in some countries for severe AD, but serious side-effects, such as dose-dependent nephrotoxicity and hypertension, limit the use of cyclosporine in the long term (10). An unmet need for treatment of moderate-to-severe AD therefore exists.

Now, and in recent years, treatments with monoclonal antibodies including dupilumab, tralokinumab, and Janus kinase (JAK) inhibitors are being developed. Dupilumab is a subcutaneously (SC) administrated antibody, directed against the interleukin (IL)-4 receptor antagonist that blocks IL-4 and IL-13 (13–22). Tralokinumab is an IL-
In addition, oral JAK inhibitors are becoming available, i.e. abrocitinib (JAK1), upadacitinib (JAK1), baricitinib (JAK 1/2) and tofacitinib (JAK 1/3) (26–32). Abrocitinib, upadacitinib and baricitinib are for oral use, while tofacitinib may be used both orally and topically (the last one as off-label).

These treatments all appear to have great potential for treatment of AD in randomized controlled trials (RCTs) against placebo. However, a lack of head-to-head (HTH) trials, as well as variability in AD study designs and outcome measures, make it difficult to compare the efficacy of these new drugs. The aim of this systematic review was to compare the efficacy of monoclonal antibodies, including dupilumab, tralokinumab, and JAK inhibitors, in patients with moderate and severe AD.

### MATERIALS AND METHODS

A systematic literature search was conducted for clinical studies, using Medline (Pubmed), EMBASE and Cochrane library to identify systemic drugs used in treatment of AD. This was investigated using the Preferred Reporting Items for Systemic Reviews and Meta-Analyses (PRISMA) guidelines (33). Two authors (F.S. and M.H.) independently searched the medical databases Pubmed, EMBASE, and Cochrane library using the following search terms: (atopic dermatitis AND (upadacitinib OR rinoq OR ABT-494) OR (baricitinib OR LY3009104) OR (olument or baricitinib) OR (dupilumab OR dupixent OR REGN668 OR SAR231893) OR (abrocitinib OR PF-04965842) OR (tralokinumab OR ct-354) OR (tofacitinib OR xeljanz) OR (Janus kinase inhibitor) OR (JAK inhibitor)). Furthermore, studies were identified by screening reference lists of key articles and review articles.

#### Inclusion and exclusion criteria

Inclusion criteria were clinical trials in English that investigated at least 10 adult patients with AD in each treatment group, who were treated with monoclonal antibodies including dupilumab, tralokinumab, or JAK inhibitors. Only phase II and III trials were included. Trials that did not include any placebo group, or did not provide detailed information about the proportion of patients achieving 50%, 75% and 90% improvement in Eczema Area and Severity Index (EASI) score, were excluded. Furthermore, trials that investigated topical treatment with monoclonal and JAK inhibitors were also excluded.

Primary outcomes were the proportion of patients achieving 50%, 75% and 90% improvement in EASI score. Studies were included only if data fulfilling EASI50, EASI-75 and EASI-90 could be extracted directly from the tables or the manuscript of the relevant studies. Secondary outcomes included mean percentage reduction in EASI score from baseline until evaluation of efficacy, and mean percentage reduction in scores for the Dermatology Life Quality Index (DLQI), Patient-Oriented Eczema Measure (POEM), Pruritus Numerical Rating Scale (NRS), Pruritus Visual Analog Scale (VAS), and proportion of patients achieving an Investigator Global Assessment (IGA) score of 0 or 1 reflecting clear or mild AD.

#### Data extraction

After inclusion of all relevant studies, the same authors independently performed data extraction. Studies were screened according to title and abstract. After all relevant studies were included, the duplicate studies were removed. The extraction data listed in tables included the name of the first author, year of publication, phase and name of clinical trial, medication and dose, number of randomized patients, mean EASI score at the beginning, age of patients, control group, information about concurrent topical treatment allowed, AD severity and information about prior treatments/ washout (Table S1). Data regarding fulfilling EASI-50, EASI-75 and EASI-90 was extracted directly from the tables of the manuscripts of the relevant studies (Table S1). If data were provided only by graphs, Engauge Digitizer Software (Engauge Digitizer (markummitchell.github.io), assessed 1 July 2021) was used to read out the data.

#### Statistical analysis

Efficacy outcomes were grouped based on doses and weeks of treatment with the relevant treatments. When statistically appropriate (same treatment agent, period of treatment and dose), meta-analyses were conducted using random-effects models by using Review Manger version 5.4 (https://training.cochrane.org/online-learning/core-software-cochrane-reviews/reviewman) assessed 26 November 2021). One outcome measure was used for meta-analyses: the risk difference (RD) for binary outcomes, both with 95% confidence interval (95% CI). The RD of 0.2 means that the risk of event in focus is 20 percentage points more likely in the experimental group than in the control group. For each outcome scale, a separate meta-analysis was performed. In the case of every treatment agent, subgroup analyses were performed depending on whether TCS were allowed (Figs S1–S6).

### RESULTS

The database search resulted in 1,614 non-duplicate studies (Fig. 1). Most studies originated as multinational studies conducted in several continents, including Europe, North America, Australia, Asia, or Latin America (15–17, 23–31). Five studies originated from North America (14, 20–22, 32) and 2 studies from Europe (18, 19). All included patients had moderate-to-severe AD.

Regarding dupilumab, the dose was either 200 or 300 mg once a week (QW) or once every other week (Q2W) in 9 studies (14–22). The dose of tralokinumab was either 45, 150, 300 mg Q2W, or once every 4 weeks (Q4W) in 3 studies (23–25). For abrocitinib, the dose was either 10, 30, 100 or 200 mg once daily in 2 studies (22, 26), for baricitinib either 1, 2 or 4 mg once daily in 4 studies (27, 29, 30, 32), and for upadacitinib either 7.5 or 15 mg in 1 study (28), or 30 mg once daily in 2 studies (28, 31). Concomitant TCS was allowed or recommended in 10 studies (17, 19, 20, 22–24, 27, 29, 30, 32) and not allowed in 9 studies (14–16, 18, 21, 25, 26, 28, 31). For further details on each study, see Table S1.

#### Meta-analysis: primary outcomes: EASI-50, EASI-75, EASI-90

**Monotherapy:** With respect to EASI-50 (7 studies, n=4,803), upadacitinib 30 mg once daily and dupilumab 200 mg QW showed comparable results after 16 weeks of treatment (upadacitinib: RD 59%, 95% CI 42–76) (dupilumab: RD 56%, 95% CI 33–78). Abrocitinib 200...
mg once daily after 16 weeks of treatment was almost as effective as dupilumab 300 mg QW after 12 weeks of treatment (abrocitinib: RD 52%, 95% subtotal CI 36–69) (dupilumab: RD 50%, CI 38–63). The response rates of upadacitinib dupilumab and abrocitinib, differed considerably with different dosages (Fig. S1).

With respect to EASI-75 (8 studies, n=5,765), treatment with upadacitinib 30 mg once daily and dupilumab 200 mg QW once again showed comparable results compared with placebo groups (upadacitinib: RD 59%, 95% CI 43–76) (dupilumab: RD 52%, 95% CI 30–74) after 16 weeks of treatment. Similar trends were observed regarding treatment with abrocitinib 200 mg once daily (abrocitinib 200 mg: RD 49%, 95% CI 32–66) and dupilumab 200 mg Q2W (dupilumab 200 mg: RD 43%, 95% CI 28–57) both after 16 weeks of treatment (Fig. S2).

With respect to EASI-90 (7 studies, n=3,621), treatment with upadacitinib 30 mg once daily after 16 weeks of treatment was superior compared with placebo group (RD 45%, 95% CI 28–57). Treatment with abrocitinib 200 mg once daily and dupilumab 200 mg QW showed comparable results (abrocitinib: RD 49%, 95% CI 32–66) and dupilumab RD 33%, 95% CI 15–52) after 16 weeks of treatment (Fig. S3).

**Combination with TCS.** With respect to EASI-50 (10 studies, n=4,646), treatment with dupilumab 300 mg Q2W and 300 mg QW after 16 weeks of treatment showed comparable results (300 mg Q2W: RD 42%, 95% 35–49) (300 mg QW: RD 41%, 95% CI 35–46). In second place, treatment with abrocitinib 200 mg once daily after 12 weeks of treatment also showed high efficacy compared with other treatments (abrocitinib 200 mg: RD 34%, 95% CI 24–43) (Fig. S4).

No studies investigated upadacitinib in combination with TCS with respect to EASI-50.

With respect to EASI-75 (10 studies, n=6,265), treatment with abrocitinib 200 mg once daily after 12 weeks of treatment was superior to other treatments (RD 43%, 95% CI 33–53). In addition, treatment with dupilumab 300 mg Q2W and 300 mg QW after 16 weeks of treatment also showed comparable results (Q2W: RD 40%, 95% CI 28–52) (Q2 RD 37%, 95% CI 30–43) (Fig. S5). No studies investigated upadacitinib in combination with TCS with respect to EASI-75.

With respect to EASI-90 (8 studies, n=5,765), treatment with abrocitinib 200 mg once daily after 12 weeks of treatment was superior to other treatments (abrocitinib: RD 52%, 95% CI 28–44). Treatment with dupilumab 300 mg Q2W and 300 mg QW after 16 weeks of treatment presented comparable results (300 mg Q2W: RD 31%, 95% CI 23–38) (300 mg QW: RD 30%, 95% CI 24–36) (Fig. S6). For more information on secondary outcomes in this study, see Table SII. No studies investigated upadacitinib in combination with TCS with respect to EASI-90.

**DISCUSSION**

This review and meta-analysis are based on 19 RCTs, including 10 studies, in which concomitant use of TCS was allowed. The work was supported by a high degree of standardization brought about by the adoption of a Core Outcome Set and ensuring agreement on outcome measures (34). The results of the current analysis highlight the major potential of JAK inhibitors and dupilumab as effective treatments in moderate-to-severe AD after only 16 weeks of treatment, both alone and in combination with TCS. To date, only a single HTH study has compared JAK inhibitors (upadacitinib) with dupilumab directly, suggesting that upadacitinib 30 mg once daily as monotherapy demonstrated superior efficacy vs dupilumab 300 mg Q2W regarding EASI-70 and EASI-90 (31). This is similar to the broad conclusions of the current study, demonstrating that upadacitinib is associated with better improvement in EASI score than dupilumab as monotherapy.

Previous review studies have investigated the efficacy of systemic therapies in atopic dermatitis (35–38). A network meta-analysis, which included only RCTs published before October 2019, concluded in agreement with the current findings that upadacitinib 30 mg once daily had the numerically highest improvement in EASI-50, EASI-75 and EASI-90 in monotherapy RCTs, and abro-
this was not possible, due to the differences in these studies, including that the review study reported only the outcomes of included studies without investigating any direct comparison of the treatment drugs (38). At the same time, in the review article, systematic treatment of AD was investigated based on different studies, including RCTs, observational and meta-analysis among both paediatric and adult patients (38). The current study results for treatment with tralokinumab were consistent with previous network meta-analysis and review studies, suggesting that treatment with abrocitinib, upadacitinib and dupilumab were most effective compared with tralokinumab (35–37).

Regarding the safety of JAK inhibitors among patients with AD, few data are available. However, the safety of JAK inhibitors seems not to be very different in the studies, when used as monotherapy (26, 28, 39). Common adverse events associated with JAK inhibitor treatment regarding AD include eczema, headache and abdominal pain (26, 28, 39). In general, common adverse events linked to JAK inhibitors include infections of the upper respiratory tract, headache or diarrhoea (40–42). Blood count alterations seem to be reversible and normalize after withdrawal (43, 44). However, an increased risk of bacterial and viral infection, such as reactivation of herpes zoster infection, has been described to be more frequent than treatment with dupilumab (45–48).

Although the overall incidence of serious adverse events associated with the use of JAK inhibitors for AD is low, data regarding the use of JAK inhibitors in other skin diseases suggest a potentially slightly increased risk of more serious adverse events, such as thromboembolic, cardiovascular and haematological events (49, 50). However, patients with AD are often younger and a relatively healthier patient population, and less susceptible to severe adverse events, compared with elderly individuals. This may be the reason why severe adverse events are less common or even unobserved in AD trials (51).

Study limitations

This study has some limitations. Only those studies investigating patients with moderate-to-severe AD were included. However, the studies used different definitions of severity. This could potentially have impact the conclusions.

The current study did not include the percentage change in EASI from baseline in the meta-analysis, since few studies provided the necessary data. This may also have had an impact on the conclusions.

There may be a risk of uneven distribution regarding studies investigating EASI-50, EASI-75 and EASI-90 as monotherapy and combination therapy. Unfortunately, upadacitinib was only presented as monotherapy and not as combination therapy, making comparison with the other drugs impossible when it comes to combination therapy. This may play a major role for the conclusion...
of this study. However, the EASI responses appear to be higher for upadacitinib and dupilumab and, compared with other agents, significant conclusions cannot be drawn due to differences in study design and dose of medication.

The efficacy and safety of the drugs included in this review were investigated in weeks 12 or 16. However, further studies are needed to determine the long-term efficacy and safety of monoclonal antibodies and JAK inhibitors. In addition, abrocitinib, upadacitinib and baricitinib have only been studied among adults and adolescents (aged 12–17 years), which limits their use among lower age groups.

**Conclusion**

This review suggests that patients who have moderate-to-severe AD unresponsive to topical therapies may benefit from treatment with JAK inhibitors, such as upadacitinib, abrocitinib, and baricitinib. In this updated systemic review and meta-analysis, treatment with upadacitinib 30 mg once daily as monotherapy had the numerically highest efficacy regarding EASI-50, EASI-75 and EASI-90. In combination therapy studies with TCS, dupilumab 300 mg Q2W had the highest efficacy regarding EASI-50, and abrocitinib 200 mg once daily had the highest score regarding EASI-75 and EASI-90. The current findings suggest that treatment with JAK inhibitors may be associated with comparable results, both as monotherapy, but also in combination therapy with TCS. However, treatment with dupilumab seems to be most effective, when in combination therapy with TCS. Treatment with abrocitinib, upadacitinib and dupilumab seems to be more effective than tralokinumab. HTH studies are required in order to place new treatments in the correct order in AD guidelines.

**Conflicts of interest:** MASH reported receiving grants from Astra Zeneca, Leo Pharma; Sanofi Genzymes and Eli Lilly. KSI has been part of advisory boards and received personal fees from CSL Behring, Regeneron, Sanofi, Boehringer Ingelheim, Union Therapeutics, and_Toosonix and personal fees from Coloplast, Chemocentryx, LEO Pharma, Incyte, Kymera, and VielaBio. KSI has been part of advisory boards and received personal fees from Astra Zeneca, Leo Pharma; Sanofi Genzymes and Eli Lilly. MASH, GBEJ and KSI declare that none of the conflicts of interest mentioned had any influence on the content of this manuscript.

**REFERENCES**

1. Odhiambo JA, Williams HC, Clayton TO, Robertson CF, Asher MJ; ISAAC Phase Three Study Group. Global variations in prevalence of eczema symptoms in children from ISAAC Phase Three. J Allergy Clin Immunol 2009; 124: 1251–1258.
2. Silverberg JI, Hanifin JM. Adult eczema prevalence and associations with asthma and other health and demographic factors: a US population-based study. J Allergy Clin Immunol 2013; 132: 1132–1138.
3. Williams HC. Atopic dermatitis: the epidemiology, causes and prevention of atopic eczema. Cambridge: Cambridge University Press; 2000.
4. Garmhausen D, Hagemann T, Bieber T, Dimitriou I, Fimmers R, Diepgen T, et al. Characterization of different courses of atopic dermatitis in adolescent and adult patients. Allergy 2013; 68: 498–506.
5. Napolitano M, Megna M, Patruno C, Gisondi P, Ayala F, Balato N. Adult atopic dermatitis: a review. Ital Dermatol Venereol 2016; 151: 403–411.
6. Bieber T. Atopic dermatitis. N Engl J Med 2008; 358: 1483–1494.
7. Katsarou A, Armenaka M. Atopic dermatitis in older patients: particular points. J Eur Acad Dermatol Venereol 2011; 25: 12–8.
8. McAleer MA, Flóhr C, Irvine AD. Management of difficult and severe eczema in childhood. BMJ 2012; 345: e4770.
9. Flóhr C, Irvine AD. Systemic therapies for severe atopic dermatitis in children and adults. J Allergy Clin Immunol 2013; 132: 774–774.
10. Sidbury R, Davis DM, Cohen DE, Cordoro KM, Berger TG, Bergman JN, et al. Guidelines for care of the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents. J Am Acad Dermatol 2014; 71: 327–349.
11. Berry R, Hanifin JM. Systemic therapy of atopic dermatitis. Clin Exp Dermatol 2000; 25: 559–566.
12. Megna M, Napolitano M, Patruno C, Villani A, Balato A, Monfrecola G, et al. Systemic treatment of adult atopic dermatitis: a review. Dermatol Ther (Heidelb) 2017; 7: 1–23.
13. Sanofi-Aventis Groupe. Dupixent. Sanofi-Aventis Groupe, Paris, France, 2017.
14. Beck LA, Thäçi D, Hamilton JD, Graham NM, Bieber T, Rocklin R, et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med 2014; 371: 130–139.
15. Simpson EL, Bieber T, Guttman-Yassky E, Beck LA, Blauvelt A, Cork MJ, et al.; SOLO 1 and SOLO 2 Investigators. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med 2016; 375: 2335–2348.
16. Thäçi D, Simpson EL, Beck LA, Bieber T, Blauvelt A, Papp K, et al. Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial. Lancet 2016; 387: 40–52.
17. Blauvelt A, de Bruin-Weller M, Goorhdam M, Cather JC, Weisman J, Pariser D, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet 2017; 389: 2287–2303.
18. Tsianakas A, Luger TA, Radin A. Dupilumab treatment improves quality of life in adult patients with moderate-to-severe atopic dermatitis: results from a randomized, placebo-controlled clinical trial. Br J Dermatol 2018; 178: 406–414.
19. de Bruin-Weller M, Thäçi D, Smith CH, Reich K, Cork MJ, Radin A, et al. Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFÉ). Br J Dermatol 2018; 178: 1083–1101.
20. Blauvelt A, Simpson EL, Tying SK, Purcell LA, Shumel B, Petro CD, et al. Dupilumab does not affect correlates of vaccine-induced immunity: a randomized, placebo-controlled trial in adults with moderate-to-severe atopic dermatitis. J Am Acad Dermatol 2019; 80: 158–167.
21. Guttman-Yassky E, Bissonnette R, Unger B, Suárez-Fariñas M, Ardeleanu M, Esaki H, et al. Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis. J Allergy Clin Immunol 2019; 143: 155–172.
22. Bieber T, Simpson EL, Silverberg JI, Thäçi D, Paul C, Pink AE, et al.; JADE COMPARE Investigators. Abrocitinib versus placebo or dupilumab for atopic dermatitis. N Engl J Med 2021; 384: 1101–1112.
23. Wollenberg A, Howell MD, Guttman-Yassky E, Silverberg JI, Kell C, Ranade K, et al. Treatment of atopic dermatitis with...
tralokinumab, an anti-IL-13 mAb. J Allergy Clin Immunol 2019; 143: 135–141.
24. Silverberg JI, Toth D, Bieber T, Alexis AF, Elewski BE, Pink AE, et al.; ECZTRA 3 study investigators. Tralokinumab plus topical corticosteroids for the treatment of moderate-to-severe atopic dermatitis: results from the double-blind, randomized, multicentre, placebo-controlled phase III ECZTRA 3 trial. Br J Dermatol 2021; 184: 450–463.
25. Wollenberg A, Blauvelt A, Guttman-Yassky E, Worm M, Lynde C, Lacour JP, et al.; ECZTRA 1 and ECZTRA 2 study investigators. Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2). Br J Dermatol 2021; 184: 437–449.
26. Gooderham MJ, Forman SB, Bissonnette R, Beebe JS, Zhang W, Banfield C, et al. Efficacy and Safety of Oral Janus Kinase 1 Inhibitor Abrocitinib for Patients With Atopic Dermatitis: A Phase 2 Randomized Clinical Trial. JAMA Dermatol 2019; 155: 1371–1379.
27. Guttman-Yassky E, Silverberg JI, Nemoto O, Forman SB, Wilke A, Prescilla R, et al. Baricitinib in adult patients with moderate-to-severe atopic dermatitis: A phase 2 parallel, double-blind, randomized placebo-controlled multiple-dose study. J Am Acad Dermatol 2019; 80: 913–921.
28. Guttman-Yassky E, Thaci D, Pangan AL, Hong HC, Papp KA, Reich K, et al. Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial. J Allergy Clin Immunol 2020; 145: 877–884.
29. Reich K, Kabashima K, Peris K, Silverberg JI, Eichenfield LF, Bieber T, et al. Efficacy and safety of baricitinib combined with topical corticosteroids for treatment of moderate to severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol 2020; 156: 1333–1343.
30. Simpson EL, Lacour JP, Spelman L, Galimberti R, Eichenfield LF, Bissonnette R, et al. Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials. Br J Dermatol 2020; 183: 242–255.
31. Blauvelt A, Teixeira HD, Simpson EL, Costanzo A, De Bruin-Weller M, Barbarot S, Prajapati VH, Lio P, Hu X, Wu T, Liu J, Ladzinski B, Chu AD, Eyerich K. Efficacy and safety of upadacitinib vs dupilumab in adults with moderate-to-severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol 2021; 157: 1047–1055.
32. Simpson EL, Forman S, Silverberg JI, Zirwas M, Mavroudis E, Han G, et al. Baricitinib in patients with moderate-to-severe atopic dermatitis: results from a randomized monotherapy phase 3 trial in the United States and Canada (BREEZE-ADS). J Am Acad Dermatol 2021; 85: 62–70.
33. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med 2009; 151: 65–94.
34. Mokkink LB, Prinsen CA, Bouter LM, Vet HC, Terwee CB. The Consensus-based Standards for the selection of health Measurement Instruments (COSMIN) and how to select an outcome measurement instrument. Braz J Phys Ther 2016; 19: 105–113.
35. Silverberg JI, Thysen JP, Fährbach K, Mickel K, Cappelleri JC, Romero W et al. Comparative efficacy and safety of systemic therapies used in moderate-to-severe atopic dermatitis: a systematic literature review and network meta-analysis. J Eur Acad Dermatol Venereol 2021; 35: 1797–1810.
36. Drucker AM, Morra DE, Prieto-Merino D, Ellis AG, Yiu ZZ, Rochwerg B, et al. Systemic immunomodulatory treatments for atopic dermatitis: update of a living systematic review and network meta-analysis. JAMA Dermatol 2022; 158: 523–532.
37. Nusbaum KB, Fleischer S, Fleischer AB Jr. Efficacy of biologics and oral small molecules for atopic dermatitis: a systematic review and meta-analysis. J Dermatolog Treat 2021; 8: 1–11.
38. Zhou S, Qi F, Gong Y, Zhang J, Zhu B. Biological therapies for atopic dermatitis: a systematic review. Dermatology 2021; 237: 542–552.
39. Li C, Sun X, Zhao K, Meng F, Li L, Mu Z, et al. Efficacy and safety of Janus kinase inhibitors for the treatment of atopic dermatitis: a systematic review and meta-analysis. Dermatology 2021; 27: 1–11.
40. Mueller RB, Hasler C, Popp F, Mattow F, Durmisi M, Souza A, et al. Effectiveness, tolerability, and safety of tofacitinib in rheumatoid arthritis: a retrospective analysis of real-world data from the St. Gallen and Aarau cohorts. J Clin Med 2019; 8: 1548.
41. Ma C, Lee JK, Mitra AR, Teriaky A, Choudhary D, Nguyen TM, et al. Systematic review with meta-analysis: efficacy and safety of oral Janus kinase inhibitors for inflammatory bowel disease. Aliment Pharmacol Ther 2019; 50: 5–23.
42. Winthrop KL, Park SH, Gul A, Cardiel MH, Gomez-Reino JJ, Tanaka Y, et al. Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis. Ann Rheum Dis 2016; 75: 1133–1138.
43. Weinhold KJ, Bukowski JF, Brennan TV, Noveck RJ, Staats JS, Lin L, et al. Reversibility of peripheral blood leukocyte phenotypic and functional changes after exposure to and withdrawal from tofacitinib, a Janus kinase inhibitor, in healthy volunteers. Clin Immunol 2018; 191: 10–20.
44. Shi JG, Chen X, Lee JK, Mitra AR, Teriaky A, Choudary D, Nguyen TM, et al. The pharmacokinetics, pharmacodynamics, and safety of baricitinib, an oral JAK 1/2 inhibitor, in healthy volunteers. J Clin Pharmacol 2014; 54: 1354–1361.
45. Curtis JR, Xie F, Yun H, Bernatsky S, Winthrop KL. Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis. Ann Rheum Dis 2016; 75: 1843–1847.
46. Winthrop KL, Wouters AG, Choy EH, Soma K, Hodge JA, Nduaka CI, et al. The safety and immunogenicity of live zoster vaccination in patients with rheumatoid arthritis before starting tofacitinib: a randomized phase II trial. Arthritis Rheumatol 2017; 69: 1969–1977.
47. Almanzar G, Kienle F, Schmalzing M, Maas A, Tony HP, Prelog M. Tofacitinib modulates the VZV-specific CD4+ T cell immune response in vitro in lymphocytes of patients with rheumatoid arthritis. Rheumatology 2019; 58: 2051–2060.
48. Winthrop KL, Yamanaka H, Valdez H, Mortensen E, Chew R, Krishnaswami S, et al. Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis. Arthritis Rheumatol 2014; 66: 2675–2684.
49. Singh R, Heron CE, Ghamrawi RI, Strowd LC, Feldman SR. Emerging role of Janus kinase inhibitors for the treatment of atopic dermatitis. Immunotargets Ther 2020; 9: 255–272.
50. Silverberg NB. Atopic dermatitis prevention and treatment. Cutis 2017; 100: 192.
51. He H, Guttman-Yassky E. JAK inhibitors for atopic dermatitis: an update. Am J Clin Dermatol 2019; 20: 181–190.